Phase 2 pivotal study of WP 1122 for treatment of COVID-2019-infections outside the U.S.
Latest Information Update: 20 Jun 2022
At a glance
- Drugs WP 1122 (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
Most Recent Events
- 16 Jun 2022 According to Moleculin Biotech media release, the company is in the process of identifying additional countries where this trial could occur.
- 12 May 2022 According to Moleculin Biotech media release, this trial will be launched in H2 2022.
- 20 Aug 2021 New trial record